March 26, 2021
Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) are associated with a substantial economic burden in the United States, according to a study published online ahead of print in the journal Current Medical Research and Opinion.
Researchers from Boehringer Ingelheim Pharmaceuticals identified commercially insured US adults diagnosed with GPP or PPP for the study and then matched them 1:3 with a plaque psoriasis cohort and a general population/control cohort.
For patients with GPP and PPP, health care resource utilization was high, findings showed. Patients with GPP had quadruple the number of inpatient visits, and patients with PPP had double the number of inpatient visits, of matched cohorts.
The study also found that patients with GPP had significantly higher total all-cause health care costs compared with matched cohorts. Cost ratios for patients with GPP were 5.58 compared with control subjects and 1.36 compared with patients with plaque psoriasis.
Patients with PPP, meanwhile, had significantly higher total all-cause health care costs compared with control subjects. Costs ratios for patients with GPP were 4.11 compared with control subjects and 1.06 compared with patients with plaque psoriasis.
“GPP and PPP patients have significant economic burden due to higher direct medical and pharmacy costs,” researchers wrote. “Further investigation is needed to better understand the drivers of economic burden in patients with GPP and PPP, and how health care resource use and costs are impacted by disease severity.”
Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States [published online ahead of print, 2021 Mar 25]. Curr Med Res Opin. 2021;1-18. doi:10.1080/03007995.2021.1894108